Susquehanna International Group
SABSW icon

Susquehanna International Group’s SAB Biotherapeutics Warrant SABSW Stock Holding History

Susquehanna International Group’s Portfolio SABSW Stock Details SABSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-26,302
Closed -$750 – 13448
2025
Q3 		$750 Buy
+26,302
New +$878 ﹤0.01% 12209
2024
Q2 		– Sell
-12,366
Closed -$482 – 13071
2024
Q1 		$482 Buy
+12,366
New +$333 ﹤0.01% 12029
2022
Q3 		– Sell
-10,944
Closed -$2K – 13994
2022
Q2 		$2K Buy
+10,944
New +$2.49K ﹤0.01% 12689

Other funds holding SABSW

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Susquehanna International Group's SABSW Position: Q4 2025 in Review

Susquehanna International Group sold out of SAB Biotherapeutics Warrant (SABSW) in Q4 2025, closing a stake of 26,302 shares — an estimated $750 sold.

Susquehanna International Group first reported a position in SABSW in Q2 2022 and held it in 3 quarters. The position peaked at $2K in Q2 2022. 7 funds tracked by Wall St. Rank hold SABSW as of Q4 2025.

  • Susquehanna International Group reported no remaining SAB Biotherapeutics Warrant position as of Q4 2025 after selling out during the quarter.
  • Susquehanna International Group sold 26,302 SAB Biotherapeutics Warrant shares in Q4 2025, an estimated $750.
  • Susquehanna International Group first reported a position in SAB Biotherapeutics Warrant in Q2 2022 and held it in 3 quarters.
  • Susquehanna International Group's SAB Biotherapeutics Warrant position peaked at $2K in Q2 2022.
  • 7 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q4 2025.

Based on Susquehanna International Group's 13F filing for Q4 2025, filed 17 Feb 2026.